laitimes

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

author:Datatreasure

China Fund Newspaper Taylor

Today's stock market, sitting for a while over the car, in the morning, once dived, more than 3,000 stocks fell, fortunately in the afternoon V came back, so that the majority of investors lost money reduced. However, the northbound funds ran 11.8 billion.

Nearly 12 billion foreign capital has fled

On November 10, the stock indexes of the two cities fell sharply in the morning, and the three major stock indexes fell by more than 1%, and the afternoon shock rebounded, and the decline was significantly narrowed. Pharmaceutical, real estate, semiconductor and other sectors are stronger, the meta-universe concept continues to be active, vaccines, generic drugs, consumer electronics and other topics have been performed, and coal, brewing, electricity and other sectors are weak. The turnover of the two cities was slightly enlarged, and the northbound funds had a large net outflow, with a net sale of more than 11 billion yuan in the whole day.

As of the close, the Shanghai index fell 0.41% to 3492.46 points, the Shenzhen component index fell 0.38% to 14515.88 points, and the ChiNext index fell 0.3% to 3399.66 points; the total turnover of the two cities was 1,080.2 billion yuan, and the net outflow of northbound funds was 11.81 billion yuan.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

Hengrui Pharmaceutical straightened up

The most eye-catching thing in today's market is the 300 billion Hengrui Pharmaceutical straight up, up more than 7.8% as of the close.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

On the news side, the national medical insurance negotiations of the star anti-cancer "miracle drug" PD-1 inhibitor were arranged today (10th). According to the feedback of on-site people, in the morning, we have seen the domestic PD-1 four people (Cinda, Baekje, Junshi and Hengrui) entering one after another. Among them, Hengrui entered the market at about 10:40 a.m. and did not see the company out of the negotiation site until nearly 1 p.m. Compared with other negotiating companies such as Cinda, Baekje and Junshi in the morning (the entry time is about 1 hour), Hengrui's entry time seems to be longer. It is understood that after the company enters the market, it may take a while to start formal negotiations, and there will be a signing link after the negotiation. The negotiation time may be unified to half an hour. This year, Hengrui PD-1 is expected to be negotiated for two indications.

Subsequently, news came from the Internet that Hengrui Pharmaceutical won the bid for the whole line. As for whether the stock price change is related to the outcome of the medical insurance negotiations, the staff responded that the medical insurance negotiations have not yet reached a result, the final result is not known at present, and there is a confidentiality agreement, which needs to wait for the medical insurance bureau to officially disclose. As for whether the sharp rise in stock prices is related to the health insurance negotiations, the staff stressed that it is not clear.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

On November 9, the three-day 2021 national medical insurance negotiations officially kicked off, and experts from the National Medical Insurance Bureau negotiated with pharmaceutical companies to reduce drug prices.

At present, most of the varieties participating in the negotiations are inferred from the "2021 National Medical Insurance Drug Catalogue Adjustment through Preliminary Review of Drugs and Information" (hereinafter referred to as the "Announcement") previously released on the official website of the National Medical Insurance Bureau. According to the announcement, a total of 271 drugs passed the formal examination, mainly Western medicines and a small number of proprietary Chinese medicines. Passing the preliminary review means that it is expected to enter the new version of the medical insurance directory through medical insurance negotiations.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

The medical insurance negotiations will involve Hengrui Pharmaceutical, BeiGene, Rongchang Biology, Roche, Pfizer and many other well-known enterprises of a number of important varieties, such as PD-1 monoclonal antibody, BTK inhibitors, PARP inhibitors, etc., dual antibodies, ADC, CAR-T and other new therapies are also expected to participate, the market attention is very hot.

The CAR-T product Agilense injection, which was just approved in early June this year, is also on the list of formalities vetting. As China's first CAR-T product, it was previously exposed to a high price of 1.2 million yuan, which is also the first time that CAR-T products have entered the national medical insurance negotiations, and the outside world has attracted much attention to whether it can negotiate successfully, and if the negotiation is successful, how much price reduction is concerned. CAR-T cell therapy is an emerging treatment method, which is the first method in China to use immune cells in the human body to treat tumors.

Watson Bio once approached a 20% limit

In addition to Hengrui Pharmaceutical, there are also 80 billion vaccine stocks in the market today, Watson Bio, which has also soared.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

The reason for the surge in Watson Bio is the approval of the third needle of the reinforcing needle.

According to the information of the government service platform of the Ministry of Science and Technology, the "Phase IIIb clinical trial evaluating the enhancement of immunogenicity and safety of the novel coronavirus mRNA vaccine in people aged 18 to 59 and 60 years old who have been vaccinated with the new coronavirus inactivated vaccine" was approved. The applicant is the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, and the approval time is November 2021.

The news may mean that the Phase III clinical trial of Watson Biological mRNA new crown vaccine sequentially inoculated with inactivated new crown vaccines for people over 18 years old (that is, the third dose of enhanced injection clinical trials) has been approved by the state.

Affected by the news, the pharmaceutical stocks rose overall today.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

The sub-new stock Tuoxin Pharmaceutical industry harvested 20% of the limit for 4 consecutive days.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

The new energy sector is killed

Affected by Tesla's 12% collapse in the US stock market last night, the new energy sector of A shares fell as a whole today, and Ning Wang once fell by 4%.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

Real estate soared

The real estate sector picked up in the afternoon. Poly Development rose more than 7%, followed by Jinke Shares, Rongsheng Development, and China International Trade.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

On the news side, on November 9, the China Interbank Market Dealers Association held a symposium for representatives of real estate enterprises. It is reported that some participating housing enterprises have plans to register and issue debt financing instruments in the interbank market in the near future. Some bond practitioners said that the convening of the symposium means that the relevant policies of real estate enterprises to issue bonds in china will be loosened, and in the near future, there will be housing enterprises issuing bond financing in the open market, and at the same time, banks and other institutional investors will also re-"transfuse" for housing enterprises through bond investment and other means to prevent further deterioration of the capital chain of housing enterprises.

Central Bank: 826.2 billion yuan of new RMB loans in October

According to preliminary statistics, the increase in the scale of social financing in October 2021 was 1.59 trillion yuan, 197 billion yuan more than the same period last year, and 721.9 billion yuan more than the same period in 2019. Among them, RMB loans issued to the real economy increased by 775.2 billion yuan, an increase of 108.9 billion yuan year-on-year; foreign currency loans issued to the real economy decreased by 3.3 billion yuan, a year-on-year decrease of 14.2 billion yuan; entrusted loans decreased by 17.3 billion yuan, down 100 million yuan year-on-year; trust loans decreased by 106.1 billion yuan, an increase of 18.6 billion yuan year-on-year; undiscounted bank acceptance bills decreased by 88.6 billion yuan, a year-on-year decrease of 20.3 billion yuan; and net financing of corporate bonds was 203 billion yuan, 23.3 billion yuan less than the same period last year The net financing of government bonds was 616.7 billion yuan, an increase of 123.6 billion yuan year-on-year; the domestic equity financing of non-financial enterprises was 84.6 billion yuan, 8.1 billion yuan less than that of the same period last year.

Broad money grew by 8.7%, and narrow money grew by 2.8%

At the end of October, the balance of broad money (M2) was 233.62 trillion yuan, an increase of 8.7% year-on-year, and the growth rate was 0.4 percentage points higher than the end of the previous month, 1.8 percentage points lower than that of the same period last year; the balance of narrow money (M1) was 62.61 trillion yuan, an increase of 2.8% year-on-year, and the growth rate was 0.9 and 6.3 percentage points lower than the end of the previous month and the same period of the previous year, respectively; the balance of currency (M0) in circulation was 8.61 trillion yuan, an increase of 6.2% year-on-year. Net cash withdrawal for the month was $78.1 billion.

Second, RMB loans increased by 826.2 billion yuan in October, and foreign currency loans increased by US$13 billion

At the end of October, the balance of local and foreign currency loans was 196.38 trillion yuan, an increase of 11.4% year-on-year. At the end of the month, the balance of RMB loans was 190.29 trillion yuan, an increase of 11.9% year-on-year, and the growth rate was the same as the end of the previous month, 1 percentage point lower than the same period last year.

RMB loans increased by RMB826.2 billion in October, an increase of RMB136.4 billion year-on-year. By sector, household loans increased by 464.7 billion yuan, of which short-term loans increased by 42.6 billion yuan, medium- and long-term loans increased by 422.1 billion yuan; enterprise (business) unit loans increased by 310.1 billion yuan, of which short-term loans decreased by 28.8 billion yuan, medium- and long-term loans increased by 219 billion yuan, bill financing increased by 116 billion yuan; non-banking financial institutions increased loans by 58.3 billion yuan.

At the end of October, the balance of foreign currency loans was US$954.4 billion, up 3.4% year-on-year. Foreign currency loans increased by $13 billion in the month, a decrease of $10.8 billion year-on-year.

In October, RMB deposits increased by 764.9 billion yuan and foreign currency deposits increased by US$21 billion

At the end of October, the balance of local and foreign currency deposits was 236.42 trillion yuan, an increase of 9.2% year-on-year. At the end of the month, the balance of RMB deposits was 229.95 trillion yuan, an increase of 9.1% year-on-year, and the growth rate was 0.5 percentage points higher than the end of the previous month and 1.2 percentage points lower than the same period last year.

RMB deposits increased by 764.9 billion yuan in October, an increase of 1.16 trillion yuan year-on-year. Among them, household deposits decreased by 1.21 trillion yuan, non-financial enterprise deposits decreased by 572.1 billion yuan, fiscal deposits increased by 1.11 trillion yuan, and non-banking financial institutions increased by 1.24 trillion yuan.

At the end of October, the balance of foreign currency deposits was $1.01 trillion, up 15.5% year-on-year. Foreign currency deposits rose $21 billion in the month, up $7.9 billion from a year earlier.

4. In October, the monthly weighted average interest rate of interbank rmb market lending and the monthly weighted average interest rate of pledge bond repurchase were both 2.04%

In October, the interbank RMB market traded a total of 94.08 trillion yuan in the form of loans, spot bonds and repurchases, with an average daily turnover of 5.53 trillion yuan, an average daily turnover of 23.5% year-on-year. Among them, the average daily transaction of interbank lending decreased by 0.5% year-on-year, the average daily transaction of spot bonds increased by 37% year-on-year, and the average daily transaction of pledge repurchase increased by 24.4% year-on-year.

The weighted average interest rate on interbank lending in October was 2.04%, 0.12 and 0.09 percentage points lower than the same period last month and the same period last year, respectively, and the weighted average interest rate on pledge repurchase was 2.04%, 0.15 and 0.18 percentage points lower than the previous month and the same period last year, respectively.

In October, RMB settlement business for cross-border trade was 617.5 billion yuan, and RMB settlement business for direct investment was 407.5 billion yuan

In October, cross-border trade in goods, trade in services and other current accounts, outward direct investment and foreign direct investment settled in RMB were 463.2 billion yuan, 154.3 billion yuan, 106.5 billion yuan and 301 billion yuan respectively.

Big news came from the Taiwan Affairs Office of the State Council

On the morning of November 10, the Taiwan Affairs Office of the State Council held a regular press conference, and spokesperson Zhu Fenglian responded to recent hot topics.

Foreign capital rarely smashed nearly 12 billion, and pharmaceutical stocks suddenly exploded! 1.2 million yuan of an anti-cancer miracle drug entered the medical insurance negotiations, and Hengrui Pharmaceutical and Watson Bio soared

The US side is urged not to send the wrong signal to the "Taiwan independence" forces

For some time now, the US side has been constantly making passive moves in selling weapons to Taiwan and strengthening US-Taiwan military ties, which has aggravated tension in the Taiwan Strait. On the evening of the 9th, US Senator Conyen and others arrived in Taiwan by military plane and will meet with Tsai Ing-wen and others.

In this regard, Zhu Fenglian, spokesperson of the Taiwan Affairs Office of the State Council, said on the 10th that we resolutely oppose any form of official exchanges and military contacts between the United States and the Taiwan region. We urge some MEMBERS of the US Congress to abide by the one-China principle and the relevant provisions of the three Sino-US joint communiques, and not to send the wrong signal to the "Taiwan independence" forces, otherwise it will only bring further damage to peace and stability in the Taiwan Strait. The DPP authorities' "relying on the United States to seek independence" is doomed to failure. No one should underestimate the strong determination, firm will and strong ability of the Chinese people to defend national sovereignty and territorial integrity!

The provocation of "Taiwan independence" does not stop for a day, and the tension in the Taiwan Strait will not slow down for a day

Taiwan's defense department recently announced that since the beginning of this year, more than 700 PLA military planes have entered the airspace of southwest Taiwan, and the military confrontation between the two sides of the strait is difficult to slow down, and Taiwan will bear greater military pressure in the future.

In this regard, Zhu Fenglian, spokeswoman for the Taiwan Affairs Office of the State Council, said that we are willing to strive for the prospect of peaceful reunification with the greatest sincerity and the greatest efforts, but we will never leave any space for various forms of "Taiwan independence" separatist activities. The root cause of the current tension in the Taiwan Strait is that the DPP authorities and the "Taiwan independence" forces are nakedly selling the "two-state theory" and colluding with external forces to constantly seek "independence" provocations. The PLA's holding of relevant training exercises is to resolutely defend state sovereignty and territorial integrity, to effectively target "Taiwan independence" separatist activities and interference by external forces, and to fundamentally safeguard the overall interests of the Chinese nation and the vital interests of compatriots on both sides of the strait. The provocation of "Taiwan independence" does not stop for a day, and the tension in the Taiwan Strait will not slow down for a day.

"Taiwan independence" means the loss of peace and the advent of disaster

The Ministry of Commerce recently issued a notice encouraging families to prepare certain necessities according to their needs, triggering speculation among mainland people about whether the two sides of the strait are about to go to war. In this regard, Zhu Fenglian, spokesperson of the Taiwan Affairs Office of the State Council, said that the Ministry of Commerce has responded to this. I hope that everyone will not believe in rumors and do not spread rumors.

According to reports, Taiwan's defense department is expected to complete the production of a "handbook for the survival and refuge of wartime people" in March next year, triggering speculation among the Taiwanese people about "armed reunification." Zhu Fenglian said: The people on both sides of the strait are very clear that "Taiwan independence" means the loss of peace and the advent of disaster. The DPP authorities stubbornly carry out "independence" provocations for the sake of their own selfish interests, and do not hesitate to tie the Taiwan people to the chariot of "Taiwan independence." This kind of perverse behavior of coercing public opinion and deviating from the general trend will greatly damage the well-being of the Taiwan compatriots and will inevitably be opposed and resisted by the Taiwan compatriots. We hope that the broad masses of Taiwan compatriots will polish their eyes, refrain from becoming victims of the "Taiwan independence" separatist forces, and jointly safeguard the vital interests of their compatriots and safeguard peace and stability in the Taiwan Strait.

Read on